Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 26, Issue 4, Pages 351-362
Publisher
Informa UK Limited
Online
2021-12-08
DOI
10.1080/14728214.2021.2015320
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
- (2021) Srdan Verstovsek et al. Future Oncology
- Phase II study of single-agent nivolumab in patients with myelofibrosis
- (2021) Iman Abou Dalle et al. ANNALS OF HEMATOLOGY
- Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis
- (2021) John Mascarenhas et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
- (2021) Francisco Cervantes et al. LEUKEMIA
- Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party
- (2021) Donal P. McLornan et al. LEUKEMIA
- TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis
- (2021) Lilian Varricchio et al. JCI Insight
- Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
- (2020) Claire N. Harrison et al. AMERICAN JOURNAL OF HEMATOLOGY
- Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
- (2020) Naveen Pemmaraju et al. BLOOD
- Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
- (2020) Naveen Pemmaraju et al. BLOOD
- A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
- (2020) Aaron T. Gerds et al. BLOOD
- Single-cell analysis based dissection of clonality in myelofibrosis
- (2020) Elena Mylonas et al. Nature Communications
- Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis
- (2020) John Mascarenhas et al. JOURNAL OF MEDICAL ECONOMICS
- Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
- (2020) Jessica Petiti et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Survival following allogeneic transplant in patients with myelofibrosis
- (2020) Krisstina Gowin et al. Blood Advances
- Peritransplantation Use of Ruxolitinib in Myelofibrosis
- (2020) Uroosa Ibrahim et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study
- (2020) Vikas Gupta et al. LEUKEMIA & LYMPHOMA
- Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
- (2020) Aaron T. Gerds et al. Blood Advances
- Luspatercept for the treatment of anemia in myelodysplastic syndromes (MDS) and primary myelofibrosis (PMF)
- (2019) Pierre Fenaux et al. BLOOD
- Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling
- (2019) Daniel A. C. Fisher et al. LEUKEMIA
- Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation
- (2019) Nico Gagelmann et al. BLOOD
- Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes and reduces bone marrow fibrosis in patients with myelofibrosis
- (2019) Naseema Gangat et al. CLINICAL CANCER RESEARCH
- Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
- (2019) Donal McLornan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Oral Idasanutlin in Patients with Polycythemia Vera
- (2019) John Mascarenhas et al. BLOOD
- Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms
- (2019) Cansu Cimen Bozkus et al. Cancer Discovery
- Systematic Literature Review of the Economic Burden and Cost of Illness in Patients with Myelofibrosis
- (2019) Derek Tang et al. BLOOD
- Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
- (2019) Francesca Palandri et al. CANCER
- Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis
- (2018) Lucia Masarova et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
- (2018) Ayalew Tefferi et al. LEUKEMIA
- Pacritinib to treat myelofibrosis patients with thrombocytopenia
- (2018) Douglas Tremblay et al. Expert Review of Hematology
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management
- (2018) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Ruxolitinib Therapy Followed by Reduced Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis – Myeloproliferative Disorders Research Consortium 114 study
- (2018) Vikas Gupta et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy
- (2018) Jack W. Singer et al. Oncotarget
- Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation
- (2018) Kavita Raj et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera
- (2017) T Tsuruta-Kishino et al. ONCOGENE
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis
- (2016) Alla Keyzner et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey
- (2016) Ruben A. Mesa et al. CANCER
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Myelofibrosis: to transplant or not to transplant?
- (2016) R. Devlin et al. Hematology-American Society of Hematology Education Program
- Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups
- (2015) H. Joachim Deeg et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
- (2015) K. P. Patel et al. BLOOD
- Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis
- (2015) N. Kroger et al. BLOOD
- Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I
- (2015) Ruben A. Mesa et al. Clinical Lymphoma Myeloma & Leukemia
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
- (2015) N M Kröger et al. LEUKEMIA
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
- (2014) F. Passamonti et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon 2a target JAK2V617F-positive progenitor and stem cells
- (2014) M. Lu et al. BLOOD
- MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
- (2014) D. Rondelli et al. BLOOD
- Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
- (2014) P. Lundberg et al. BLOOD
- Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis
- (2014) Ramy A. Abdelrahman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis
- (2014) Rajasekhar N V S Suragani et al. NATURE MEDICINE
- Blockade of oncogenic I B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
- (2014) M. Ceribelli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rationale for Targeting the PI3K/Akt/mTOR Pathway in Myeloproliferative Neoplasms
- (2013) Niccolò Bartalucci et al. Clinical Lymphoma Myeloma & Leukemia
- Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: A biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy
- (2013) Marco Ruella et al. EXPERIMENTAL HEMATOLOGY
- Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)
- (2013) T Zhou et al. LEUKEMIA
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
- (2013) Michaela Waibel et al. Cell Reports
- Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon- 2a specifically targets JAK2V617F-positive polycythemia vera cells
- (2012) M. Lu et al. BLOOD
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sequential or combination therapy for multiple myeloma
- (2012) Ajay Nooka et al. Expert Review of Hematology
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells
- (2010) M. Lu et al. BLOOD
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Suppression of inflammation by a synthetic histone mimic
- (2010) Edwige Nicodeme et al. NATURE
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms
- (2009) Lizz F. Grimwade et al. BRITISH JOURNAL OF HAEMATOLOGY
- Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence
- (2008) J.-J. Lataillade et al. BLOOD
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
- (2008) Gerlinde Wernig et al. CANCER CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started